Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)

/PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), pioneer in enzyme technology for rare immunological conditions, has today on June 30,...

Related Keywords

Sweden ,United States ,Stockholm ,American ,Hansa Biopharma ,Andreas Eggert ,Klaus Sindahl ,Eva Nilsag ,Anders Gersel Pedersen ,Hilary Malone ,Prnewswire Hansa Biopharma ,Peter Nicklin ,Katja Margell ,Share Rights Program ,Audit Committee ,Remuneration Committee ,Hansa Biopharma Option Program ,Nomination Committee ,Exchange Commission ,Head Of Corporate Communications ,Us Committee ,Scientific Committee ,Nasdaq Stockholm ,Annual General ,Annual General Meeting ,Chief Executive Officer ,Mats Blom ,American Depositary Shares ,Rights Program ,Adoption Program ,Annual General Meetings ,Corporate Communications ,Hansa Biopharma Ab ,